Last $1.50 USD
Change Today +0.0316 / 2.15%
Volume 28.2K
BSPM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

biostar pharmaceuticals inc (BSPM) Snapshot

Open
$1.53
Previous Close
$1.47
Day High
$1.53
Day Low
$1.46
52 Week High
03/6/14 - $3.49
52 Week Low
10/24/13 - $0.95
Market Cap
23.2M
Average Volume 10 Days
58.2K
EPS TTM
$0.17
Shares Outstanding
15.5M
EX-Date
--
P/E TM
8.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSTAR PHARMACEUTICALS INC (BSPM)

Related News

No related news articles were found.

biostar pharmaceuticals inc (BSPM) Related Businessweek News

No Related Businessweek News Found

biostar pharmaceuticals inc (BSPM) Details

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People’s Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for the treatment of chronic hepatitis B. Its current product line also includes 5 other OTC products, 10 prescription-based pharmaceuticals, 6 nutriceuticals or health products, and 1 medical device. The company’s OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat pain, headache, and fever; and Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for the treatment of pain and other symptoms associated with menstruation. Its prescription pharmaceutical products include Danshen granule for the treatment of coronary heart disease, myocarditis, and angina pectoris; and Taohuasan pediatric medicine for the treatment of bronchial congestion and coughs in children. In addition, the company manufactures hernia belt, a medical device used for the relief of hernia. Further, it provides nutrient and OTC products, which comprise Tangning capsule for the treatment of diabetes; Yizi capsule for fertility; Shengjing capsule for kidney; and Aoxing ointment to treat psoriasis, vitiligo, and various dermatitis. Additionally, the company operates zggbyy.com, a Website that serves as Internet-based China Hepatitis Internet hospital, which provides HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through 68 distributors and a network of approximately 226 dedicated sales people in approximately 27 provinces. The company is headquartered in Xianyang, the People’s Republic of China.

438 Employees
Last Reported Date: 03/31/14

biostar pharmaceuticals inc (BSPM) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $17.4K
Interim Chief Financial Officer, Principal Ac...
Total Annual Compensation: $11.0K
Chief Operating Officer
Total Annual Compensation: $6.6K
Compensation as of Fiscal Year 2013.

biostar pharmaceuticals inc (BSPM) Key Developments

Biostar Pharmaceuticals Hires Xiaohui Zheng as Chief Scientist

Biostar Pharmaceuticals, Inc. announced that the company has hired Professor Xiaohui Zheng as its chief scientist to preside over the company's product development projects. Professor Xiaohui Zheng, born in March 1968, is a professor and Director of the Engineering Research Center for the modernisation of Chinese herbal medicine at Northwestern University, and is mainly engaged in the traditional Chinese medicine compound effects of metabolism and composition analysis, biological chromatographic analysis of new technologies and innovative drug development.

Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results of the Second Quarter and Six Months Ended June 30, 2014

Biostar Pharmaceuticals, Inc. announced unaudited consolidated financial results of the second quarter and six months ended June 30, 2014. For the quarter, the company reported sales, net of $19,198,854 against $14,650,854 for the same period of last year. The increase is mainly attributable to the increase in sales volume of other Aoxing products, hospital products, and Weinan products and the addition of 2 new products at Aoxing. Income from operations was $455,348 against loss from operations of $794,732 for the same period of last year. Income before income taxes was $1,178,845 against loss before income taxes of $562,214 for the same period of last year. Net income was $1,645,494 against net loss of $730,980 for the same period of last year. Net earnings per basic and diluted share were $0.11 against net loss per basic and diluted share of $0.06 for the same period of last year. For the six months, sales, net were $32,380,018 against $26,742,763 for the same period of last year. Loss from operations was $307,764 against $63,618 for the same period of last year. Income before income taxes was $1,784,756 against $526,345 for the same period of last year. Net income was $1,952,164 against net loss of $170,006 for the same period of last year. Net earnings per basic and diluted share were $0.14 against net loss per basic and diluted share of $0.02 for the same period of last year. Net cash provided by operating activities was $1,036,577 against $10,477,322 for the same period of last year. Purchase of property and equipment was $479,792 against $955,052 for the same period of last year.

Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Biostar Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the period, the company reported sales, net of $13,181,164 against $12,091,909 a year ago. Loss from operations was $763,112 against income from operations of $731,114 a year ago. Income before income taxes was $605,911 against $1,088,559 a year ago. Net income was $306,670 or $0.02 per basic and diluted share against $560,974 or $0.06 per basic and diluted share a year ago. Net cash provided by operating activities was $3,104,261 against $6,179,389 a year ago. Purchase of property, plant and equipment was $1,957 against $4,352 a year ago. The increase in revenue was mainly attributable to the increase in sales volume of other Aoxing products and Weinan products and the addition of 4 new products at Shaanxi Weinan. The increase in sales volume is mainly due to the positive image spread by the hospital using products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSPM:US $1.50 USD +0.0316

BSPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSPM.
View Industry Companies
 

Industry Analysis

BSPM

Industry Average

Valuation BSPM Industry Range
Price/Earnings 7.5x
Price/Sales 0.4x
Price/Book 0.3x
Price/Cash Flow 7.8x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSTAR PHARMACEUTICALS INC, please visit www.biostarpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.